219 related articles for article (PubMed ID: 16696787)
21. Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?
Camilleri M
Neurogastroenterol Motil; 2007 Feb; 19(2):77-84. PubMed ID: 17244161
[TBL] [Abstract][Full Text] [Related]
22. Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis.
Suh DC; Kahler KH; Choi IS; Shin H; Kralstein J; Shetzline M
Aliment Pharmacol Ther; 2007 Mar; 25(6):681-92. PubMed ID: 17311601
[TBL] [Abstract][Full Text] [Related]
23. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?
Andresen V; Hollerbach S
Drug Saf; 2004; 27(5):283-92. PubMed ID: 15061683
[TBL] [Abstract][Full Text] [Related]
24. The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.
Nakai A; Diksic M; Kumakura Y; D'Souza D; Kersey K
Neurogastroenterol Motil; 2005 Apr; 17(2):212-21. PubMed ID: 15787942
[TBL] [Abstract][Full Text] [Related]
25. Alosetron use drops dramatically with risk management.
Traynor K
Am J Health Syst Pharm; 2004 Jun; 61(12):1210-2. PubMed ID: 15259746
[No Abstract] [Full Text] [Related]
26. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Andresen V; Montori VM; Keller J; West CP; Layer P; Camilleri M
Clin Gastroenterol Hepatol; 2008 May; 6(5):545-55. PubMed ID: 18242143
[TBL] [Abstract][Full Text] [Related]
27. Irritable bowel syndrome. New treatment drug on the market.
Harv Health Lett; 2000 Jun; 25(8):7. PubMed ID: 10810051
[No Abstract] [Full Text] [Related]
28. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
Shah E; Kim S; Chong K; Lembo A; Pimentel M
Am J Med; 2012 Apr; 125(4):381-93. PubMed ID: 22444104
[TBL] [Abstract][Full Text] [Related]
29. Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
Avigan M; Justice R; Mackey AC; Nair N
Am J Gastroenterol; 2003 Sep; 98(9):2105-6. PubMed ID: 14499800
[No Abstract] [Full Text] [Related]
30. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
Komoto S; Miura S
Nihon Rinsho; 2006 Aug; 64(8):1487-90. PubMed ID: 16898618
[TBL] [Abstract][Full Text] [Related]
31. Ischemic colitis during treatment with alosetron.
Friedel D; Thomas R; Fisher RS
Gastroenterology; 2001 Feb; 120(2):557-60. PubMed ID: 11159896
[TBL] [Abstract][Full Text] [Related]
32. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
Lembo AJ; Olden KW; Ameen VZ; Gordon SL; Heath AT; Carter EG
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):675-82. PubMed ID: 15290660
[TBL] [Abstract][Full Text] [Related]
33. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.
Lembo A; Weber HC; Farraye FA
Drugs; 2003; 63(18):1895-905. PubMed ID: 12930162
[TBL] [Abstract][Full Text] [Related]
34. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Lewis JH
Drug Saf; 2011 Jul; 34(7):545-65. PubMed ID: 21663331
[TBL] [Abstract][Full Text] [Related]
35. FDA draws patients into alosetron risk management.
Miller JL
Am J Health Syst Pharm; 2000 Oct; 57(19):1736. PubMed ID: 11030021
[No Abstract] [Full Text] [Related]
36. Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.
Kawano K; Mori T; Fu L; Ito T; Niisato T; Yoshida S; Shiokawa S; Sato Y; Murakami H; Shishikura T
Neurogastroenterol Motil; 2005 Apr; 17(2):290-301. PubMed ID: 15787949
[TBL] [Abstract][Full Text] [Related]
37. Ischemic colitis, irritable bowel syndrome, and tegaserod--an alternative viewpoint.
Shetzline MA; Cohard-Radice M; Joelsson B
Pharmacotherapy; 2005 Nov; 25(11):1684-5; discussion 1685. PubMed ID: 16232032
[No Abstract] [Full Text] [Related]
38. Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System.
Bielefeldt K
Dig Dis Sci; 2016 Sep; 61(9):2655-65. PubMed ID: 27073073
[TBL] [Abstract][Full Text] [Related]
39. Irritable bowel syndrome genophenomics: correlation of serotonin-transporter polymorphisms and alosetron response.
Scherl E; Frissora CL
Pharmacogenomics J; 2003; 3(2):64-6. PubMed ID: 12746730
[No Abstract] [Full Text] [Related]
40. Serotonergic agents and the irritable bowel syndrome: what goes wrong?
Spiller R
Curr Opin Pharmacol; 2008 Dec; 8(6):709-14. PubMed ID: 18672092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
